Runx2 downregulation, migration and proliferation inhibition in melanoma cells treated with BEL β-trefoil

Oncol Rep. 2017 Apr;37(4):2209-2214. doi: 10.3892/or.2017.5493. Epub 2017 Mar 6.

Abstract

Malignant melanoma is a lethal form of skin cancer and highly metastatic tumor with poor prognosis; BEL β-trefoil, a lectin, obtained by our group, possesses the ability to act specifically on malignant cells. Therefore, the aim of our study was to investigate the effects of BEL β-trefoil in melanoma cells in an attempt to evaluate its potential usage as anticancer agent. BEL β-trefoil was purified by chromatography and A375 and MeWo melanoma cells were treated. Viability and proliferation were evaluated as well as apoptosis, RUNX2 gene expression and migration ability. The treated tumor cells decreased viability as well as proliferative ability. Flow cytometry analysis showed a lessen effect of the treatment on apoptosis. The gene expression analysis showed a reduction of RUNX2 expression in a dose-dependent manner and migration ability was reduced significantly in both treated cell lines. Our findings suggest that BEL β-trefoil can be considered a useful tool against malignancy due to its effect based on the simultaneous proliferation ability reduction as well as the inhibition of migration capacity on melanoma tumor cells.

MeSH terms

  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Core Binding Factor Alpha 1 Subunit / genetics*
  • Dose-Response Relationship, Drug
  • Down-Regulation*
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Lotus / metabolism
  • Melanoma / drug therapy
  • Melanoma / genetics*
  • Plant Lectins / pharmacology*

Substances

  • Core Binding Factor Alpha 1 Subunit
  • Plant Lectins
  • RUNX2 protein, human